Covestor LTD Alnylam Pharmaceuticals, Inc. Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Covestor LTD holds 457 shares of ALNY stock, worth $124,404. This represents 0.08% of its overall portfolio holdings.

Number of Shares

457

Previous 776 41.11%

Holding current value

$124,404

Previous $189,000 33.33%

% of portfolio

0.08%

Previous 0.12%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$233.81 - $287.01 $74,585 - $91,556	-319 Reduced 41.11%	457 $126,000
Q2 2024 Aug 09, 2024	BUY	$143.31 - $247.0 $6,305 - $10,868	44 Added 6.01%	776 $189,000
Q1 2024 May 10, 2024	BUY	$146.51 - $198.2 $54,941 - $74,325	375 Added 105.04%	732 $110,000
Q4 2023 Feb 09, 2024	BUY	$151.41 - $196.57 $44,363 - $57,595	293 Added 457.81%	357 $68,000
Q3 2023 Nov 13, 2023	SELL	$170.77 - $211.65 $512 - $634	-3 Reduced 4.48%	64 $11,000
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $185 - $212	1 Added 1.52%	67 $13,000
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $2,739 - $3,532	-15 Reduced 18.52%	66 $13,000
Q4 2022 Feb 13, 2023	SELL	$185.53 - $241.31 $58,256 - $75,771	-314 Reduced 79.49%	81 $19,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $41,562 - $69,600	300 Added 315.79%	395 $79,000
Q2 2022 Aug 10, 2022	BUY	$120.42 - $169.29 $240 - $338	2 Added 2.15%	95 $14,000
Q1 2022 May 13, 2022	BUY	$127.18 - $173.91 $4,705 - $6,434	37 Added 66.07%	93 $15,000
Q4 2021 Feb 10, 2022	BUY	$159.56 - $209.29 $8,935 - $11,720	56 New	56 $10,000

Others Institutions Holding ALNY

# of Institutions

639

Shares Held

108M

Call Options Held

2.11M

Put Options Held

2.04M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.5B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account